Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets
Real-world evidence and longer clinical trial follow-up show no increased incidence of serious adverse events Additional post-hoc data analyses support sustained efficacy of cladribine tablets in patients with relapsing MS with high disease activity Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the presentation of new data for cladribine tablets at…
